

Treatment of Eosinophilic Esophagitis: Is Oral Viscous Budesonide Superior to Swallowed Fluticasone Spray?

Somashekar G. Krishna, MD, MPH¹
 Bobby R. Kakati, MD²
 Kevin W. Olden, MD³
 Daniel K. Brown, MD¹

¹*Division of Gastroenterology and Hepatology,*
²*Department of Internal Medicine, University of Arkansas*
for Medical Sciences, Little Rock, Arkansas; ³*Section*
of Gastroenterology, Georgetown University Hospital/
Washington Hospital Center, Washington, DC

Eosinophilic esophagitis (EoE) is an immunologic reaction to ingested or inhaled allergens characterized by esophageal eosinophilia and gastrointestinal symptoms. In adults, this disease is more common in men than women, with a mean age of onset of 38 years. Recent data show that EoE is increasing in prevalence, with an incidence of 6–30 cases per 100,000 individuals.¹

Case Report

A 28-year-old man presented with a long history of dysphagia and at least 2 episodes of food impaction. He was a nonsmoker, maintained a very healthy lifestyle, had a history of allergic rhinitis, and had a brother with EoE. An esophagogastroduodenoscopy (EGD) performed in 2007 revealed considerable esophageal trachealization and stenosis, which prevented complete passage of a standard gastroscope. Esophageal biopsies confirmed EoE (applying diagnostic guidelines). The patient was started on fluticasone propionate (FP) 220 mcg (2 puffs swallowed twice daily) and was instructed not to rinse his mouth, eat, or drink for 30–60 minutes after taking the medication. A repeat EGD with attempted dilatation was performed in early 2008 due to the lack of symptomatic improvement after 4 months of therapy. Concentric rings were seen (starting at the midesophagus), and luminal narrowing was noted. Controlled radial expansion (CRE) balloon dilatation to 8–10 mm failed to disrupt the mucosa; satisfactory mucosal disruption was obtained after CRE dilatation to 10–12 mm. Due to postprocedural chest

pain, the patient underwent a chest radiograph, which demonstrated subcutaneous emphysema in the neck and superior mediastinum, resulting in a diagnosis of esophageal perforation. After hospital observation, the patient was discharged without requiring surgical intervention. Adjunctive management of EoE consisted of thorough allergy testing, including an allergy skin prick test and a specific immunoglobulin (Ig)E antibody assay to various food allergens (ImmunoCAP, Quest Diagnostics).² Total IgE was markedly elevated, with a reported value of approximately 500 IU/mL (normal range, 4–60 IU/mL). The patient was placed on a modified diet but did not experience significant symptom improvement.

In the middle of 2008, the patient presented with persistent dysphagia refractory to diet restriction and treatment with swallowed FP and a proton pump inhibitor. Initial management included the addition of montelukast (10 mg daily). Due to the lack of symptomatic relief, we discontinued swallowed FP and started treatment with oral viscous budesonide (BUD). As presented in recent pediatric studies, viscous BUD was prepared by dissolving 1 BUD 0.5-mg respule (Pulmicort, AstraZeneca) in five 1-g packets of sucralose (Splenda, McNeil Nutritionals), for a total volume of 10–15 mL, dosed at 0.5 mg twice daily.³ Data were collected using the Modified Mayo Dysphagia Questionnaire to assess treatment response.^{1,4} Following initiation of viscous BUD therapy, the patient reported significant improvement in dysphagia and greater tolerance of dietary variety (Tables 1 and 2). He was placed on an improved or extended diet. The dosage of viscous BUD was decreased to 0.5 mg every other day during the winter (December–February), with sustained control of symptoms. The patient noted a worsening of symptoms in the spring/pollen season (March–April); consequently, BUD dosage was increased to 0.5 mg twice daily

Address correspondence to:

Dr. Somashekar G. Krishna, Division of Gastroenterology and Hepatology,
 University of Arkansas for Medical Sciences, 4301 W. Markham St, Slot 567,
 Little Rock, AR 72205; E-mail: sgkrishna@uams.edu

Table 1. Improvement in Diet After Treatment with BUD

Restricted diet on FP	Diet improvement on BUD
Whey protein shakes	Rice
Blended yogurt, pudding	All cooked vegetables* (peas, onions)
Soft cheeses	Bread*, cake, doughnuts, muffins
Nonchunky dips (cheese, ranch, bean dip)	Thin deli meat*, chicken nuggets, meat†
Oatmeal, grits	Toasted waffles, pastries
Eggs	Thin crust pizza
Turkey bacon	Onion rings, French fries
Tomato soup	Chips
Instant potatoes, baked beans	Biscuits (flaky type)

*Most notable differences (as per patient).

†The only meats that the patient is able to eat are chicken, pork, or red meat (when tender, ground, or processed). The patient is allergic to apple, banana, celery, and soy-based products.

BUD=budesonide (0.5-mg respule dissolved in five 1-g packets of sucralose, volume of 10–15 mL); FP=fluticasone propionate (metered-dose inhaler).

(Table 3). Given the patient's history of esophageal perforation, he repeatedly declined to undergo a follow-up EGD. Post-treatment morning cortisol levels were unchanged at 24 and 52 weeks of therapy.

Discussion

Our patient experienced a sustained response to viscous BUD treatment during a follow-up period of 12 months. Previous treatment with swallowed FP over more than 1 year had failed to provide therapeutic relief. Universally accepted treatment guidelines for EoE have not been developed. Available treatment options include hypoallergenic diets (dietary restriction, elimination diet, elemental formulas), topical corticosteroids, mast-cell inhibitors (sodium chromoglycate), leukotriene inhibitors (montelukast), and esophageal dilatation.

In 2 recent, double-blind, placebo-controlled, randomized controlled trials (RCTs), treatment with viscous BUD in children and nebulized BUD in adults achieved significant improvement in symptoms and endoscopic and histologic scores; the histologic endpoint (HEP) of no more than 6 eosinophils/high power field (HPF) was observed in 87% of 15 children over 3 months and in 72.2% of 15 adults and adolescents over 15 days.^{5,6} These results are better when compared to another double-

Table 2. Results of the Patient's Modified Mayo Dysphagia Questionnaire* While on a Restricted Diet†

Month and year	April 2009	May 2009	June 2009
Weeks of therapy	0	4	8
Drug and dosage	FP 220 mcg BID	BUD 0.5 mg BID	BUD 0.5 mg BID
Difficulty swallowing			
Severity	3	0	0
Frequency	3	0	0
Heartburn			
Severity	1	1	1
Frequency	3	3	1
Nausea			
Severity	1	1	0
Frequency	1	1	0
Abdominal pain			
Severity	1	1	0
Frequency	1	1	0

*The severity and frequency of belching, chest pain, regurgitation, and waking at night were reported as "0."

†The patient was placed on a restricted diet when treated with FP (Table 1). The severity and frequency of each symptom was graded on a scale from 0 to 3, in which 0 signified the absence of the symptom.

BUD=budesonide (0.5-mg respule dissolved in five 1-g packets of sucralose, volume of 10–15 mL); FP=fluticasone propionate (metered-dose inhaler).

blind, placebo-controlled RCT in children using swallowed FP, with 50% of 20 patients responding to therapy (significant at HEP ≤ 1 eosinophil/HPF; no statistical difference at HEP ≤ 6 eosinophils/HPF).⁷ The only other RCT involving steroids compared oral prednisone with swallowed FP.⁸

Two abstracts were also recently presented. One reported the results of a non-RCT in which BUD was combined with rincinol containing polyvinylpyrrolidone (Butler) at a dose of 3 mg/10 cc twice daily; 75% of 16 patients reported improvement in dysphagia (56% with complete resolution), and 33% of 8 patients thought that viscous BUD was more effective than swallowed FP.⁹ In the other trial, a double-blind RCT involving 36 patients, viscous BUD suspension (at 1 mg/4 mL twice daily) was administered for active EoE. Approximately 61% of patients (11/18) in the viscous BUD group achieved

Table 3. Results of the Patient's Modified Mayo Dysphagia Questionnaire* While on an Improved Diet† After Starting BUD Therapy

Month and year	June 2009	October 2009	December 2009	February 2010	March 2010	April 2010	May 2010
Weeks of therapy	8	24	32	40	44	48	52
Dosage of BUD	0.5 mg BID	0.5 mg BID	0.5 mg QOD	0.5 mg QOD	0.5 mg QD	0.5 mg QD	0.5 mg BID
Difficulty swallowing							
Severity	1	1	1	1	2	3	1
Frequency	2	2	1	1	3	3	2
Heartburn							
Severity	1	1	1	1	1	1	1
Frequency	1	1	1	1	1	1	1
Nausea							
Severity	0	0	0	0	1	1	0
Frequency	0	0	0	0	1	2	0
Abdominal pain							
Severity	0	0	0	0	0	1	0
Frequency	0	0	0	0	0	1	0

*The severity and frequency of belching, chest pain, regurgitation, and waking at night were reported as "0."

†The patient was placed on an improved diet when treated with BUD (Table 1). The severity and frequency of each symptom was graded on a scale from 0 to 3, in which 0 signified the absence of the symptom.

BUD=budesonide (0.5-mg respule dissolved in five 1-g packets of sucralose, volume of 10–15 mL).

remission (HEP <5 eosinophils/HPF) compared to 5.7% (1/28) in the placebo group.¹⁰

No RCTs have been conducted to evaluate esophageal dilatation, and no guidelines have been established regarding the duration of medical therapy before attempting dilatation. Mucosal tears and subsequent perforations usually result from esophageal remodeling and development of strictures. In this context, viscous BUD therapy has been associated with improvements in epithelial remodeling.¹¹ Further studies are needed to prove that medical therapy (viscous BUD vs swallowed FP) would improve epithelial remodeling, thus preventing the need for dilatation.

Some patients with EoE experience seasonal variations in symptoms that correlate with seasonal changes in esophageal eosinophil levels.¹² Over our patient's 1-year follow-up, the therapeutic dosage of viscous BUD was decreased during the winter and increased at the onset of spring.

Results from clinical and pharmacokinetic studies in bronchial asthma and inflammatory bowel disease (IBD) appear to favor the use of BUD over FP in EoE. Most studies conducted in the management of asthma have shown that inhaled BUD undergoes reversible conjugation with intracellular fatty acids, prolonging airway retention, whereas inhaled FP does not undergo intracellular esterification and, thus, may have less tracheobronchial retention.¹³ Inhaled FP is highly lipophilic and poorly water-soluble; in contrast, inhaled BUD is water-soluble and readily dissolves in mucosal fluids.^{14,15} Oral enteric-coated (EC) BUD (~9 mg/day) is equivalent to prednisolone (~40 mg/day) and superior to placebo for induction of remission in active Crohn's disease (CD).¹⁶ Budesonide enema is effective and better than placebo for treatment of distal ulcerative colitis (UC) and proctitis.¹⁷ In treatment of active CD, oral FP was associated with poor clinical efficacy compared to prednisolone; for treatment of UC, oral FP was not as effective as prednisolone and no more

effective than placebo.¹⁸⁻²⁰ These studies suggest that oral FP is inferior to EC BUD for treatment of IBD; however, no comparative studies have yet been conducted. Whether the observed difference is due to insufficient dosage, inadequate bioavailability, or the highly lipophilic nature of oral FP in the gastrointestinal tract has yet to be determined. We hypothesize that BUD is superior to FP for treatment of gastrointestinal inflammatory conditions and theorize that for oral administration, swallowed FP provides less surface area over which the drug is effective than viscous BUD.

Dosing equivalency in asthmatic patients is based upon a double-blind, placebo-controlled, crossover study comparing single doses of inhaled BUD and inhaled FP (at 400 ug, 1,000 ug, 1,600 ug, and 2,000 ug).²¹ At least 2-fold greater adrenal suppression was noted due to inhaled FP compared to the microgram-equivalent dose of inhaled BUD. Similar to the treatment of asthma, the current EoE therapeutic dosage of viscous BUD is twice the microgram-equivalent dose of swallowed FP.^{3,5}

A Cochrane meta-analysis compared markers of adrenal function (morning cortisol and 24-hr urinary cortisol) between inhaled FP and inhaled BUD at a dose ratio of 1:2 in patients with chronic asthma and found no significant difference between treatment groups.²² An extensive review summarizing 25 years of inhaled BUD use with different doses among diverse populations documented infrequent adverse events (adrenal crisis, reduced height, risk of fractures, and pregnancy complications).²³ For IBD treatment, a recent Cochrane review summarized multiple studies comparing response to adrenocorticotropic hormone (ACTH) stimulation. Treatment with EC BUD (3–15 mg/day) was significantly less likely than conventional corticosteroids (prednisone 20–40 mg/day) but more likely than placebo to cause an abnormal response to ACTH stimulation.¹⁶ Hypocortisolism due to BUD should be uncommon at an EoE treatment dose of 1–2 mg per day. Patients requiring long-term therapy should nonetheless be observed for hypothalamic-pituitary-adrenal axis suppression, oral candidiasis, and osteoporosis.

Sucralose, a substituted disaccharide, is stable at a low pH, is water-soluble, and is nonbioaccumulative. Following consumption, 85% of sucralose is excreted unchanged in feces and 15% of absorbed sucralose is excreted unchanged in urine. Sucralose does not serve as a substrate for intestinal microflora.²⁴ Rincinol containing polyvinylpyrrolidone was used in one study.⁹ This compound is a muco-adherent that forms a thin, protective coating over oral mucosa. Between these 2 compounding agents, we recommend sucralose for preparing viscous BUD doses, given its wider availability, extensively studied safety profile, and effective application in multiple RCTs.

In conclusion, larger studies of adults are needed to recommend viscous BUD as first-line therapy for EoE. An exclusively formulated viscous BUD for EoE that provides effective drug delivery should be developed. The long-term safety profile of BUD in the treatment of EoE should also be established. The dosage of BUD may need to be adjusted seasonally according to symptom variation. For treatment-refractory patients, a trial of viscous BUD can be attempted before proceeding with esophageal dilatation. In the interim, viscous BUD is an excellent alternative to swallowed FP for treating patients with EoE, and it may be the first-choice treatment in some patients.

References

1. Veerappan GR, Perry JL, Duncan TJ, et al. Prevalence of eosinophilic esophagitis in an adult population undergoing upper endoscopy: a prospective study. *Clin Gastroenterol Hepatol*. 2009;7:420-426, 426.e1-2.
2. Hamilton RG. Clinical laboratory assessment of immediate-type hypersensitivity. *J Allergy Clin Immunol*. 2010;125:S284-S296.
3. Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. *Am J Gastroenterol*. 2007;102:2271-2279; quiz 2280.
4. Grudell AB, Alexander JA, Enders FB, et al. Validation of the Mayo Dysphagia Questionnaire. *Dis Esophagus*. 2007;20:202-205.
5. Dohil R, Newbury R, Fox L, Bastian J, Aceves S. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. *Gastroenterology*. 2010;139:418-429.
6. Straumann A, Conus S, Degen L, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. *Gastroenterology*. 2010;139:1526-1537, 1537.e1.
7. Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. *Gastroenterology*. 2006;131:1381-1391.
8. Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. *Clin Gastroenterol Hepatol*. 2008;6:165-173.
9. Neumann D, Alexander G, Farrugia G, et al. A new therapy for eosinophilic esophagitis in adults: efficacy of budesonide-rincinol gel for 6 weeks in patients with dysphagia. *Am J Gastroenterol*. 2008;103:19.
10. Straumann A, Degen L, Felder S, et al. Budesonide as induction treatment for active eosinophilic esophagitis in adolescents and adults: a randomized, double-blind, placebo-controlled study (Bee-1 trial). *Gastroenterology*. 2008;134:A104.
11. Aceves SS, Newbury RO, Chen D, et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. *Allergy*. 2010;65:109-116.
12. Almansa C, Krishna M, Buchner AM, et al. Seasonal distribution in newly diagnosed cases of eosinophilic esophagitis in adults. *Am J Gastroenterol*. 2009;104:828-833.
13. Tunek A, Sjödin K, Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. *Drug Metab Dispos*. 1997;25:1311-1317.
14. Thorsson L, Edsbacker S, Kallen A, Lofdahl CG. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. *Br J Clin Pharmacol*. 2001;52:529-538.
15. Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. *Thorax*. 2003;58:258-260.
16. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. *Cochrane Database Syst Rev*. 2008:CD000296.
17. Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. *Gastroenterology*. 1998;115:525-532.
18. Wright JP, Jarnum S, Schaffalitzky de Muckadell O, Keech ML, Lennard-Jones JE. Oral fluticasone propionate compared with prednisolone in treatment

of active Crohn's disease: a randomized double-blind multicentre study. *Eur J Gastroenterol Hepatol*. 1993;5:499-503.

19. Hawthorne AB, Record CO, Holdsworth CD, et al. Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis. *Gut*. 1993;34:125-128.

20. Angus P, Snook JA, Reid M, Jewell DP. Oral fluticasone propionate in active distal ulcerative colitis. *Gut*. 1992;33:711-714.

21. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. *Thorax*. 1996;51:262-266.

22. Adams N, Lasserson TJ, Cates CJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. *Cochrane Database Syst Rev*. 2007;CD002310.

23. Christensson C, Thoren A, Lindberg B. Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects. *Drug Saf*. 2008;31:965-988.

24. Grotz VL, Munro IC. An overview of the safety of sucralose. *Regul Toxicol Pharmacol*. 2009;55:1-5.

Review

Therapeutic Options for Eosinophilic Esophagitis

Jeffrey A. Alexander, MD

David A. Katzka, MD

*Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota*

Eosinophilic esophagitis (EoE) is an allergy-based disease with a genetic predisposition in which esophageal exposure to food antigens, perhaps primed by respiratory or extraesophageal allergic disease, has been postulated to contribute to a chronic inflammatory state, eventually resulting in fibrosis and stricture formation. As with many allergies, one of the mainstays of treatment for EoE is the use of steroids. Indeed, steroids are the only pharmacologic treatment that has shown clear benefit in EoE across numerous studies. Several studies, including double-blind, placebo-controlled trials, have demonstrated the efficacy of either systemic or topical steroids in treating EoE.¹⁻⁵ With emerging data and growing enthusiasm for understanding and treating this disease, physicians are now asking questions about which steroid preparations are most effective, for how long, and at what dose. Through good anecdotal evidence, the interesting case

report by Krishna and associates proposes that viscous budesonide should comprise first-line treatment for patients with EoE.⁶ Before embarking on a discussion of which steroid is most effective, however, it is important to consider several caveats when analyzing this case report and EoE studies in general.

First, several studies evaluating the efficacy of steroids in EoE patients use symptoms as the primary endpoint. Unfortunately, in both children and adults, it has been well demonstrated that symptomatic response may not correlate with histologic response.⁷ This finding may have several explanations. The use of standardized dysphagia scoring systems, which are useful for other dysphagic diseases, may be inadequate for evaluating EoE. Symptoms may be infrequent, particularly in adults, making it difficult to demonstrate a significant difference over a short time period. The effect of short-term steroids on symptomatic fibrotic strictures may be suboptimally appreciated at endoscopy, particularly with diffuse esophageal narrowing.

Second, not all studies agree on how to define histologic remission in response to therapy. For example, some studies define less than 1 eosinophil/high power field (HPF) as a complete response, whereas other studies use 0-6 eosinophils/HPF. Some studies may use scoring systems combining eosinophil counts with other histologic parameters such as basal zone thickness. Moreover, although all studies use HPF as the gold standard field of measurement, the diameter of this field (and, therefore, the eosinophil count) may vary widely among studies. Thus, when analyzing efficacy among various steroid preparations, one should be aware that comparisons may not be of equivalent units.

Third, studies with steroids have used different preparations, dosages, and durations of therapy. For example, a standard dose of 4 puffs of 220 micrograms

Address correspondence to:

Dr. David A. Katzka, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Avenue SW, Rochester, Minnesota 55905; Tel: 507-284-1649; E-mail: Katzka.david@mayo.edu